Medigen Vaccine, Dynavax begin phase II trial for subunit COVID-19 vaccine

By The Science Advisory Board staff writers

January 25, 2021 -- Medigen Vaccine Biologics and Dynavax Technologies have dosed the first participant in a phase II clinical trial evaluating Medigen's COVID-19 vaccine candidate, MVC-COV1901, a subunit vaccine with a recombinant spike-2P antigen adjuvanted with Dynavax's CpG 1018.

The spike-2P antigen is a trimeric and prefusion stable recombinant protein developed by the U.S. National Institutes of Health (NIH). Medigen has obtained the global technology license for spike-2P from the U.S. Vaccine Research Center at NIH. The new study is based on positive phase I interim data demonstrating a good safety profile and encouraging immunogenicity of the vaccine candidate.

The phase II trial, located in Taiwan, is a randomized, double-blinded, multicenter trial expected to enroll 3,700 healthy subjects, 20 years of age and older. It will evaluate safety and immunogenicity with a dosing regiment of two intramuscularly administered doses one month apart.


Copyright © 2021 scienceboard.net
 
To access all The ScienceBoard content create a free account now:


Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.


Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
 
I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.

Already have an account? Sign in here